Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations

Many hold that the so-called golden era of antibiotic discovery has passed, leaving only a limited clinical pipeline for new antibiotics. A logical conclusion of such arguments is that we need to reform the current system of antibiotic drug research—including clinical trials and regulatory requireme...

Descrizione completa

Salvato in:  
Dettagli Bibliografici
Autori: Hey, Spencer Phillips (Autore) ; Kesselheim, Aaron S. (Autore)
Tipo di documento: Elettronico Articolo
Lingua:Inglese
Verificare la disponibilità: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Pubblicazione: 2017
In: The Hastings Center report
Anno: 2017, Volume: 47, Fascicolo: 2, Pagine: 16-20
Accesso online: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002c 4500
001 1937531465
003 DE-627
005 20251218054938.0
007 cr uuu---uuuuu
008 251002s2017 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.685  |2 doi 
035 |a (DE-627)1937531465 
035 |a (DE-599)KXP1937531465 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Hey, Spencer Phillips  |e VerfasserIn  |4 aut 
245 1 0 |a Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Many hold that the so-called golden era of antibiotic discovery has passed, leaving only a limited clinical pipeline for new antibiotics. A logical conclusion of such arguments is that we need to reform the current system of antibiotic drug research—including clinical trials and regulatory requirements—to spur activity in discovery and development. The United States Congress in the past few years has debated a number of bills to address this crisis, including the 2012 Generating Antibiotic Incentives Now Act and the 2016 21st Century Cures Act. Experts have also sought to advance antibiotic development by encouraging greater use of trials with noninferiority hypotheses, which are thought to be easier to conduct. The goal underlying these proposals is to stave off the post-antibiotic era by expanding the pharmaceutical armamentarium as quickly as possible. But although new antibiotic agents are necessary to combat the long-term threat of drug-resistant disease, we argue that these research policies, which effectively lower the bar for antibiotic approval, are ethically problematic. Rather, given broader public health considerations related to the full lifecycle of antibiotic use—including development of resistance—we should reject an overly permissive approach to new antibiotic approval and instead set the bar for regulatory approval at a point that will naturally direct research resources toward the most transformative chemical or social interventions. 
700 1 |a Kesselheim, Aaron S.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 47(2017), 2, Seite 16-20  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:47  |g year:2017  |g number:2  |g pages:16-20 
856 4 0 |u https://doi.org/10.1002/hast.685  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.685  |x Verlag  |z lizenzpflichtig  |3 Volltext  |7 1 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4779657644 
LOK |0 003 DE-627 
LOK |0 004 1937531465 
LOK |0 005 20251002055618 
LOK |0 008 251002||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2025-09-26#576D71037F893083EF17855314DCCFC0007D6034 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixrk  |a ixzs  |a zota  |a tiep 
LOK |0 939   |a 02-10-25  |b l01 
ORI |a SA-MARC-ixtheoa001.raw